The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation
Peng Liu, Liwei Zhao, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
Topics & Concepts
VenetoclaxImmunosurveillanceImmune systemApoptosisCancer researchDendritic cellBiologyImmunologyLeukemiaChronic lymphocytic leukemiaGeneticsImmunotherapy and Immune ResponsesCAR-T cell therapy researchCell death mechanisms and regulation